Memantine Hydrochloride Aspire Pharma

Memantine Hydrochloride, the active ingredient in Memantine Hydrochloride Aspire Pharma, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is prescribed to treat cognitive decline associated with Alzheimer’s disease in adult patients. The medication works by modulating glutamatergic activity to reduce neuronal excitotoxicity. It is indicated for patients with moderate to severe stages of the disease and is administered under medical supervision.

GNH USA supplies Memantine Hydrochloride Aspire Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride is used in the management of neurodegenerative disorders that involve glutamatergic excitotoxicity, primarily Alzheimer’s disease. Alzheimer's disease (moderate to severe): helps maintain cognition and functional abilities in patients with advanced disease. Alzheimer's disease (mild to moderate): may delay progression of memory loss during early stages. Alzheimer's disease (behavioral symptoms): can reduce agitation and aggression in some patients.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic injury or elevated liver enzymes

Precautions for Memantine Hydrochloride include careful assessment before use. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests during therapy. - History of seizures: use with caution as the drug may lower seizure threshold. - Elderly patients: increased sensitivity to adverse effects; start at lower doses. - Concomitant NMDA antagonists: avoid combined use to prevent additive neurotoxicity. - Store at ambient temperature: keep in the original container, protect from moisture.

Memantine Hydrochloride may interact with other medicines. Major Interactions (Avoid): - Concurrent use with other NMDA antagonists (e.g., amantadine) – increased risk of neurotoxicity. - Strong CYP3A4 inhibitors – may raise memantine plasma concentrations. Moderate Interactions (Monitor Closely): - Diuretics such as furosemide – can increase memantine levels. - Anticholinergic agents – may reduce the drug’s therapeutic effect. - Non‑steroidal anti‑inflammatory drugs – may elevate the risk of peripheral edema.